CO2024000763A2 - Composiciones y métodos de los anticuerpos anti-pacap - Google Patents

Composiciones y métodos de los anticuerpos anti-pacap

Info

Publication number
CO2024000763A2
CO2024000763A2 CONC2024/0000763A CO2024000763A CO2024000763A2 CO 2024000763 A2 CO2024000763 A2 CO 2024000763A2 CO 2024000763 A CO2024000763 A CO 2024000763A CO 2024000763 A2 CO2024000763 A2 CO 2024000763A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
pacap antibodies
antibodies
pacap
Prior art date
Application number
CONC2024/0000763A
Other languages
English (en)
Inventor
Anthony Gerard Doyle
Adam Clarke
Danyal Butt
David Laine
Hugh Macrae
Jenny Vo
Julia Rozenfeld
Sachin Surade
Original Assignee
Cephalon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Llc filed Critical Cephalon Llc
Publication of CO2024000763A2 publication Critical patent/CO2024000763A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se refiere en general a los anticuerpos anti-PACAP, las composiciones farmacéuticas que comprenden dichos anticuerpos y los métodos de producción y uso de dichos anticuerpos.
CONC2024/0000763A 2021-07-29 2024-01-26 Composiciones y métodos de los anticuerpos anti-pacap CO2024000763A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226875P 2021-07-29 2021-07-29
PCT/US2022/074238 WO2023010065A2 (en) 2021-07-29 2022-07-28 Compositions and methods for anti-pacap antibodies

Publications (1)

Publication Number Publication Date
CO2024000763A2 true CO2024000763A2 (es) 2024-04-18

Family

ID=85088265

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0000763A CO2024000763A2 (es) 2021-07-29 2024-01-26 Composiciones y métodos de los anticuerpos anti-pacap

Country Status (11)

Country Link
US (1) US20230212281A1 (es)
EP (1) EP4377343A2 (es)
KR (1) KR20240046192A (es)
AR (1) AR126603A1 (es)
AU (1) AU2022317808A1 (es)
CA (1) CA3227549A1 (es)
CO (1) CO2024000763A2 (es)
IL (1) IL310329A (es)
PE (1) PE20240809A1 (es)
TW (1) TW202317643A (es)
WO (1) WO2023010065A2 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358576B (zh) * 2013-02-20 2020-05-05 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
MA43567A (fr) * 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
TWI770020B (zh) * 2016-04-15 2022-07-11 丹麥商Ｈ朗德貝克公司 人類化抗pacap 抗體及其用途
WO2018152687A1 (en) * 2017-02-22 2018-08-30 I-Mab Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof

Also Published As

Publication number Publication date
KR20240046192A (ko) 2024-04-08
EP4377343A2 (en) 2024-06-05
WO2023010065A2 (en) 2023-02-02
AU2022317808A1 (en) 2024-02-08
TW202317643A (zh) 2023-05-01
US20230212281A1 (en) 2023-07-06
IL310329A (en) 2024-03-01
AR126603A1 (es) 2023-10-25
PE20240809A1 (es) 2024-04-18
WO2023010065A3 (en) 2023-03-16
CA3227549A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
UY38140A (es) Picolinamidas como fungicidas
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CO6541621A2 (es) Anticuerpos que se unen preferencialmente al dominio 4 extracelular de csf 1r humano y uso de los mismos
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
CO2024000890A2 (es) Compuestos de heteroarilo para tratar la enfermedad de huntington
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2023008643A2 (es) Anticuerpos anti-hla-g y uso de estos
AR112587A1 (es) Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima
CO2023013171A2 (es) Composiciones que comprenden un polipéptido variante y usos de las mismas
CO2022009068A2 (es) Composición para la inhibición de la producción de hmf que comprende disacárido de alulosa
CO2019011271A2 (es) Análogos de deutetrabenazina, su preparación y uso
CL2021001511A1 (es) Novedosa psicosa-6-fosfato fosfatasa, composición para la producción de psicosa que comprende la misma y procedimiento para la producción de psicosa mediante el uso de la misma
CO2023011697A2 (es) Composiciones que comprenden un polipéptido cas12i4 variante y usos de las mismas
CL2020002058A1 (es) Piridincarboxamidas novedosas.
CO2024000763A2 (es) Composiciones y métodos de los anticuerpos anti-pacap
CO2019011980A2 (es) Formas cristalinas de (s)-afoxolaner
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CO2022008308A2 (es) Tieniloxazolonas y análogos